Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga®

22-May-2015 - United Kingdom

Genzyme, a Sanofi company, announced that it has received the 2015 Industry Innovation Award from the National Organization for Rare Disorders (NORD) in recognition of Cerdelga® (eliglustat) capsules. Genzyme was selected for the company’s work in bringing an additional treatment option to patients with Gaucher disease. Cerdelga is the only first-line oral therapy for certain adult Gaucher disease type 1 patients.

“Cerdelga is an important option for people living with Gaucher disease, and underscores Genzyme’s commitment to understand and respond to the needs of patients living with a rare disease,” said Peter L. Saltonstall, President and CEO, NORD. "We applaud Genzyme’s dedication to providing more choices to patients in rare disease communities and are pleased to present them with NORD’s 2015 Industry Innovation Award."

Genzyme has been researching an oral therapy for Gaucher disease for fifteen years, from early chemistry and preclinical research through clinical development. The Cerdelga clinical development program is the largest ever conducted in Gaucher disease, with approximately 400 patients treated in 29 countries.

"We are proud to receive this award. The approval of Cerdelga exemplifies our commitment to bring innovative therapies forward to improve patients’ lives through ongoing research,” said Genzyme’s Head of Rare Diseases, Richard Peters, MD, Ph.D.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?